A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab

Since the beginning of the pandemic, numerous national and international clinical trials have been conducted with a large number of drugs. Many of them are intended for the treatment of other pathologies; however, despite the great effort made, no specific drug is available for the treatment of the...

Descripción completa

Detalles Bibliográficos
Autores: Villaescusa Castillo, Lucinda|||0000-0001-7187-5515, Zaragoza García, Francisco, Gayo Abeleira, Irene|||0000-0002-3596-4032, Zaragozá Arnáez, Cristina|||0000-0002-4768-6797
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Alcalá (UAH)
Repositorio:e_Buah Biblioteca Digital Universidad de Alcalá
Idioma:inglés
OAI Identifier:oai:ebuah.uah.es:10017/64284
Acceso en línea:http://hdl.handle.net/10017/64284
https://dx.doi.org/10.1007/s12325-022-02042-3
Access Level:acceso abierto
Palabra clave:COVID-19
Cytokine release syndrome
Interleukin-6
Monoclonal antibodies
Siltuximab
Farmacia
Pharmacy
id ES_fa7804ca87847f8e534e024fd7afdc5e
oai_identifier_str oai:ebuah.uah.es:10017/64284
network_acronym_str ES
network_name_str España
repository_id_str
spelling A new approach to the management of COVID-19. Antagonists of IL-6: SiltuximabVillaescusa Castillo, Lucinda|||0000-0001-7187-5515Zaragoza García, FranciscoGayo Abeleira, Irene|||0000-0002-3596-4032Zaragozá Arnáez, Cristina|||0000-0002-4768-6797COVID-19Cytokine release syndromeInterleukin-6Monoclonal antibodiesSiltuximabFarmaciaPharmacySince the beginning of the pandemic, numerous national and international clinical trials have been conducted with a large number of drugs. Many of them are intended for the treatment of other pathologies; however, despite the great effort made, no specific drug is available for the treatment of the symptoms of respiratory disease caused by SARS-CoV-2 infection. The aim of this article is to provide data to justify the use of drugs to tackle the effects produced by IL-6 as the main inflammatory mediator in patients with COVID-19 with severe respiratory complications, considering all clinical evidence linking the poor prognosis of these patients with increased IL-6 levels in the context of cytokine release syndrome. Furthermore, data are provided to justify the proposal of a rational dosing of siltuximab, a monoclonal antibody specifically targeting IL-6, based on RCP levels, considering the limited results published so far on the use of this drug in COVID-19. A literature search was conducted on the clinical trials of siltuximab published to date as well as on the different IL-6 signalling pathways and the effects of its overexpression. Knowledge of the mechanisms of action on these pathways may provide important information for the design of drugs useful in the treatment of these patients. This article describes the characteristics, properties, mechanism of action, therapeutic uses and clinical studies conducted with siltuximab so far. The results confirm that administration of siltuximab downregulates IL-6 levels, thereby reducing the inflammatory process in COVID-19 patients with severe respiratory disease, suggesting that it can be successfully used to prevent cytokine release syndrome and death from this cause.Springer Nature20222022-02-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10017/64284https://dx.doi.org/10.1007/s12325-022-02042-3reponame:e_Buah Biblioteca Digital Universidad de Alcaláinstname:Universidad de Alcalá (UAH)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ebuah.uah.es:10017/642842026-06-18T11:13:07Z
dc.title.none.fl_str_mv A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
title A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
spellingShingle A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
Villaescusa Castillo, Lucinda|||0000-0001-7187-5515
COVID-19
Cytokine release syndrome
Interleukin-6
Monoclonal antibodies
Siltuximab
Farmacia
Pharmacy
title_short A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
title_full A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
title_fullStr A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
title_full_unstemmed A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
title_sort A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
dc.creator.none.fl_str_mv Villaescusa Castillo, Lucinda|||0000-0001-7187-5515
Zaragoza García, Francisco
Gayo Abeleira, Irene|||0000-0002-3596-4032
Zaragozá Arnáez, Cristina|||0000-0002-4768-6797
author Villaescusa Castillo, Lucinda|||0000-0001-7187-5515
author_facet Villaescusa Castillo, Lucinda|||0000-0001-7187-5515
Zaragoza García, Francisco
Gayo Abeleira, Irene|||0000-0002-3596-4032
Zaragozá Arnáez, Cristina|||0000-0002-4768-6797
author_role author
author2 Zaragoza García, Francisco
Gayo Abeleira, Irene|||0000-0002-3596-4032
Zaragozá Arnáez, Cristina|||0000-0002-4768-6797
author2_role author
author
author
dc.subject.none.fl_str_mv COVID-19
Cytokine release syndrome
Interleukin-6
Monoclonal antibodies
Siltuximab
Farmacia
Pharmacy
topic COVID-19
Cytokine release syndrome
Interleukin-6
Monoclonal antibodies
Siltuximab
Farmacia
Pharmacy
description Since the beginning of the pandemic, numerous national and international clinical trials have been conducted with a large number of drugs. Many of them are intended for the treatment of other pathologies; however, despite the great effort made, no specific drug is available for the treatment of the symptoms of respiratory disease caused by SARS-CoV-2 infection. The aim of this article is to provide data to justify the use of drugs to tackle the effects produced by IL-6 as the main inflammatory mediator in patients with COVID-19 with severe respiratory complications, considering all clinical evidence linking the poor prognosis of these patients with increased IL-6 levels in the context of cytokine release syndrome. Furthermore, data are provided to justify the proposal of a rational dosing of siltuximab, a monoclonal antibody specifically targeting IL-6, based on RCP levels, considering the limited results published so far on the use of this drug in COVID-19. A literature search was conducted on the clinical trials of siltuximab published to date as well as on the different IL-6 signalling pathways and the effects of its overexpression. Knowledge of the mechanisms of action on these pathways may provide important information for the design of drugs useful in the treatment of these patients. This article describes the characteristics, properties, mechanism of action, therapeutic uses and clinical studies conducted with siltuximab so far. The results confirm that administration of siltuximab downregulates IL-6 levels, thereby reducing the inflammatory process in COVID-19 patients with severe respiratory disease, suggesting that it can be successfully used to prevent cytokine release syndrome and death from this cause.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-02-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10017/64284
https://dx.doi.org/10.1007/s12325-022-02042-3
url http://hdl.handle.net/10017/64284
https://dx.doi.org/10.1007/s12325-022-02042-3
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:e_Buah Biblioteca Digital Universidad de Alcalá
instname:Universidad de Alcalá (UAH)
instname_str Universidad de Alcalá (UAH)
reponame_str e_Buah Biblioteca Digital Universidad de Alcalá
collection e_Buah Biblioteca Digital Universidad de Alcalá
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425214227480576
score 15.812455

Similares en LA Referencia